Cell and Gene Therapies / edited by Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard.
Colaborador(es): Perales, Miguel-Angel, editor literario | Abutalib, Syed A, editor literario
| Bollard, Catherine, editor literario | SpringerLink (Online service)
.
Tipo de material:
E-bookSeries (Medicine (Springer-11650)).Advances and Controversies in Hematopoietic Transplantation and Cell Therapy,Editor: Cham : Springer International Publishing : Imprint: Springer, 2019Descripción: VI, 288 páginas 12 ilustraciones, 11 ilustraciones a color.ISBN: 9783319543680.Tema: Hematology | Hematology | Oncology Recursos en línea: Acceso a este recurso digital (usuarios Universidad Europea de Valencia)
| Tipo de ítem | Biblioteca actual | Colección | Signatura topográfica | Estado | Fecha de vencimiento | Código de barras | Reserva de ítems | |
|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Valencia Digital Acceso Electrónico (UEV) | Ciencias de la Salud | RM301.37 .C45 2019EB (Navegar estantería(Abre debajo)) | Acceso electrónico |
Navegando Valencia Digital estanterías, Ubicación en estantería: Acceso Electrónico (UEV) Cerrar el navegador de estanterías (Oculta el navegador de estanterías)
| RM301.27 .O53 2020 EB Phase I Oncology Drug Development | RM301.3.G45 J356 2021 EB Textbook of Personalized Medicine | RM301.3 .P47 2020 EB Personalized and Precision Medicine Informatics A Workflow-Based View | RM301.37 .C45 2019EB Cell and Gene Therapies | RM302 .D78 2018 EB Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions | RM302 .D78 2018 EB Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions | RM302.5 .S53 2018 EB Side Effects of Medical Cancer Therapy: Prevention and Treatment |
Historical perspective and current focus -- Part I: Genetically modified T cells (Chimeric antigen receptors and T cell receptors): Chimeric antigen receptor-T cells: Antigen selection, CAR development and future prospects -- Chimeric antigen receptor-T cells for leukemias in children: Methods, data and challenges -- Chimeric antigen receptor-T cells for leukemias in adults- Methods, data and challenges -- Chimeric antigen receptor-T cells for lymphomas: Methods, data and challenges -- T-cell receptors-gene modified T-cells for cancer -- Methods, data and challenges. -- Part II: Beyond chimeric antigen receptor and T-cell receptors - Data, Consensus & Challenges: Cytotoxic T cells for infections: From donor-specific to “off the shelf” -- Donor lymphocyte infusion in different transplant settings: When and how?- T-regulatory cells: Broadening applicability -- Tumor infiltrating lymphocytes: Current concepts and practices -- Part III: Beyond T-cells: Natural killer cells: What have we learned?- Dendritic cells in hematopoietic cell transplantation -- Mesenchymal stem cells: From bench to bedside and back -- Cell Therapies: Regulatory concerns and data collection -- Part IV: Gene Therapy: Gene therapy for hematologic malignancies and in transplant setting -- Gene therapy for nonmalignant disorders -- Future prospects of cell and gene therapies.
In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee.
No hay comentarios en este titulo.